Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved all patent litigation related to Axsome’s product SUNOSI (solriamfetol). The litigations resulted from submission of Abbreviated New Drug Applications […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.